Nonnecrotizing granulomas in the affected organ are the hallmark of sarcoidosis. This review summarizes most recent genetic findings in sarcoidosis with a focus on genes that might influence granuloma formation or resolution. Specific results in multiple ethnic groups and certain clinical subphenotypes, such as extrapulmonary organ involvement, are discussed.
INTRODUCTION
In recent years, our knowledge on the genetic background of sarcoidosis has grown substantially because of modern technology allowing genomewide association mapping and the investigation of large-size populations of different ethnicities. Many of these sarcoidosis risk variants are assumed to influence the formation of granulomatous structures in the affected organ, a hallmark of sarcoidosis pathogenesis. This review summarizes most recent genetic findings in sarcoidosis, with a focus on granuloma-relevant factors including HLA-alleles.
T-CELL ACTIVATION THROUGH HLA-ALLELES
One important aspect in granuloma formation is the activation of T cells by antigen-presenting cells through a molecular interaction of the T-cell receptors and antigen-presenting molecules. The latter are genetically encoded in the HLA region on chromosome 6p21.3, which is characterized by extreme genetic diversity. Over 7000 specific combinations of HLA variants, so-called HLA-haplotype alleles, are known today [1] . This great diversity evolved as an adaptation to disease pathogens, as allelic variation resulted in HLA molecules with different binding affinities for pathogenic targets. The world-wide distribution of HLA-alleles reflects migration patterns as well as pathogen-driven balancing selection (reviewed in [2] ). Until recently, the identification of HLA-alleles carried by an individual was costly, applying Sanger sequencingbased typing. Imputation of HLA-alleles from genome-wide genotype data, as well as next-generation sequencing methods, now allows for high-throughput HLA-typing at a lower cost [3] [4] [5] .
Certain HLA-alleles are well known to influence susceptibility to sarcoidosis and disease course (reviewed in [6] ). Of those, HLA-DRB1-alleles confer the highest risks on the population level. An excerpt of known HLA-associations with sarcoidosis and its subphenotypes is given in Table 1 [7-11,12 && , [13] [14] [15] [16] [17] , with a focus on risk alleles and recent reports comprising rather large study populations.
DIAGNOSTIC VALUE OF HLA INFORMATION
In addition to its functional role in the pathogenesis of sarcoidosis, HLA alleles have potential to aid clinical decisions with regards to sarcoidosis subphenotypes. Extra-thoracic manifestations, as well as the course of the disease, are associated with specific HLA alleles. For instance, variation at the HLA-DRB1 locus is associated with disease course [13, [18] [19] [20] [21] [22] and organ-specific involvement [8, 11] in sarcoidosis. Grunewald and Eklund [14] demonstrated that 95% of Ã03-positive patients with Löfg-ren's syndrome experienced disease resolution within 2 years, whereas disease resolved for only half of Ã03-negative patients. Subsequent work by Grunewald and his group [9] showed that DRB1Ã14 and DRB1Ã15 tended to increase the risk for a nonresolving disease, but DRB1Ã14 had a more pronounced effect on non-Löfgren syndrome patients, whereas DRB1Ã15 has a greater effect on Löfgren syndrome patients with DRB1Ã03 predominating over DRB1Ã15 in terms of increasing the likelihood of resolving disease. Interestingly, in a Han Chinese population, it was HLA-BÃ51, not DRB1Ã03, that most strongly associated with Löfg-ren syndrome [7] , suggesting that the DRB1Ã03 association with acute disease may be specific to European populations.
Until recently, DRB1 associations with sarcoidosis phenotypes have never been evaluated in African Americans. Levin et al. [12 && ] examined DRB1 variation in the context of disease phenotype in 1277 African Americans patients and 1468 controls. They found that the DRB1Ã03 : 02 allele conferred a similar likelihood of resolving disease in African American sarcoidosis patients as Ã03 : 01-positivity does in Europeans [14] . Although the DRB1Ã03 : 01 allele is found less frequently in African Americans [11] , the Ã03 : 02 allele could have similar clinical implications as the Ã03 : 01 allele in sarcoidosis patients of European ancestry [23] . As HLA genes are known to be inherited in haplotype blocks, information about the ancestral background at a HLA locus may include more than the risk effect of an allele at that locus. In analyses stratified by local ancestry Levin et al. found that the associations of HLA-DRB1Ã03 : 01 and Ã03 : 02 with susceptibility and DRB1Ã03 : 01 with persistent disease were dependent on local ancestry (European or African) at DRB1. Replication of DRB1Ã03 : 02 association with resolving disease in African American sarcoidosis patients is needed before any conclusions can be made about its potential impact on disease course.
Levin et al. [12 && ] further showed carriage of DRB1Ã0301 decreased risk for extra-pulmonary manifestations of sarcoidosis in nonthoracic lymph nodes, eyes, skin and liver. Alternatively, carriage of DRB1Ã0302 increased risk for skin involvement in African American sarcoidosis patients. In a Scandinavian population, Darlington et al. [16] showed that non-Löfgren syndrome sarcoidosis patients more frequently than Löfgren syndrome patients have extrapulmonary involvement. Although this in itself is not a novel finding, the investigators found unique associations with HLA-DRB1 alleles and risk of extra-thoracic disease manifestations depending upon Löfgren syndrome status. In Löfgren syndrome patients, DRB1Ã03 significantly decreased risk for extra-thoracic disease, but in non-Löfgren syndrome patients it was carriage of DRB1Ã11, Ã13 or Ã14 that decreased risk for extra-thoracic disease and carriage of DRB1Ã04 that increased risk for extra-thoracic disease.
As was discussed earlier, ethnicity clearly plays a role in HLA-DRB1 associations. This is further evidenced by the study of Ozyilmaz et al. [10] who found DRB1Ã11 also significantly decreased risk for extra-thoracic disease in a Turkish population, in agreement with findings of Darlington et al. in Scandanavian non-Löfgren cases. A nation-wide study of tissue confirmed sarcoidosis in Iceland from 1981 to 2004 found several different significant associations between HLA alleles and sarcoid-related arthritis [15] . HLA-B8 and HLA-B14 were more common among those who suffered from sarcoid
KEY POINTS
Granulomatous processes in sarcoidosis are assumed to be influenced by genetic risk factors at the level of antigen-presentation (HLA class II genes), immune cell activation (TNF, BTNL2, IL23R) and apoptosis (ANXA11, XAF1).
Genetic associations in sarcoidosis are partly phenotype-specific and depend on the ethnic background of an individual.
Variants in granuloma-relevant genes may be applied for the prediction of disease phenotype and therapy response in sarcoidosis.
arthritis as was carriage of the HLA-DRB1Ã03 allele. Alternatively, the HLA-DRB1Ã04 allele was significantly less common in sarcoid arthritis sufferers. This is in contrast to the findings of Darlington et al. in terms of DRB1Ã04 increasing risk for extra-thoracic disease in Scandanavians. Sato et al. [8] showed that over 40% of British patients who suffer from sarcoid uveitis carry the DRB1Ã04 allele. The risk for uveitis for DRB1Ã04 carriers is even higher in the Japanese, but because this allele is much less frequent in the Japanese population, the vast majority of sarcoidosis uveitis patients carry other DRB1 alleles. In general, HLA genotype and predicting sarcoid organ involvement is confounded by ethnicity and the attendant genetic background.
HLA CLASS II ANTIGENS
Crucial for granuloma formation is the existence and the presentation of an antigen that initiates this process. The class II molecules, such as HLA-DRB1, bind peptides on the surface of antigen-presenting cells, which are subsequently recognized by CD4þ T cells. The capacity of docking an antigenic peptide depends on genetically encoded polymorphic residues in the binding pockets [24, 25] . Investigators have therefore performed studies to identify the sarcoidosis antigen(s) with a strong binding affinity to specific HLA class II DR epitopes. In sarcoidosis, T-cell-mediated immune responses to mycobacterial antigens have been shown to be dependent upon DRB1 genotype [26] . In-silico predictions of peptide-binding affinities [27] can be used to predict which DRB1 allele/antigen combinations are likely to initiate the most robust immune response. For example, an in-silico analysis found that patients with Löfgren's syndrome express HLA-DR alleles capable of binding a significantly higher number of bacterial epitopes than other HLA-DR alleles [28] . Interestingly, DRB1Ã03 : 01 shows the highest predicted binding to Mycobacterium tuberculosis epitopes [29] . Given the affinity for Ã03 : 01 encoded epitopes to bind to M. tuberculosis-derived peptides, a potential model for exposure to this antigen involving effective clearance and subsequent self-limiting Löfg-ren's disease would seem very credible.
Mechanistic studies have provided additional insight into variation at the HLA class II loci and immune response to putative sarcoidosis antigens. ESAT-6 is a secretory protein and potent T-cell antigen produced by M. tuberculosis. A high percentage of sarcoidosis patients appear to have been previously exposed to ESAT-6, as evidenced by a positive T-cell response to different ESAT-6 peptides [30] . HLA-DRB1Ã1101 is a known sarcoidosis risk allele in both Europeans and African Americans [11] . Oswald-Richter et al. [26] showed that carriage of DRB1Ã1101 was strongly associated with a more robust Th1-response upon exposure to ESAT-6 in both European and African American sarcoidosis patients. These findings lay the ground work for gene-environment studies focused on HLA genotypes and targeted antigens known to elicit Th-1 immune responses observed in sarcoidosis.
Another similar line of mechanistic research has used patients who are positive for the HLA-DRBÃ03 genotype to study self-antigens that can sustain an inflammatory response in lungs. Wahlstrom et al. [31] used lung cells from 16 HLA-DRB1Ã0301-positive patients obtained by bronchoalveolar lavage and identified 78 amino acid sequences from self-proteins presented in the lungs of sarcoidosis patients, some of which were well known autoantigens such as vimentin and ATP synthase. Subsequent work by this same group examined the antigenic potential of these self-antigens, and found in peripheral blood that strong T-cell responses to a peptide derived from the cytoskeletal protein vimentin were present in a majority of DRB1Ã0301-positive patients with active disease, but not in patients with other HLA types [32] . Although the importance of HLA-DRB1Ã0301 in acute sarcoidosis cannot be understated, given that most sarcoidosis patients are not DRB1Ã0301 positive, further work is needed to better understand the antigens with high binding affinity to other sarcoid-DRB1-associated alleles that might subsequently stimulate an active immune response.
OTHER GRANULOMA-PROMOTING GENETIC FACTORS
Genome-wide genetic screening approaches revealed a number of novel susceptibility factors for sarcoidosis, some of which are very likely to affect granuloma formation. A splicing variant in the BTNL2 gene had first been reported with regards to sarcoidosis by Valentonyte et al. in a German study sample [33] . The protein functions as a negative costimulator in T-cell activation. In mice, it was shown that BTNL2 controls mucosal inflammation by promoting FOXP3 expression and thereby the development of regulatory T cells [34] . The genetic association of the BTNL2 variant with sarcoidosis has been confirmed in various populations, including African Americans and Japanese [17, [35] [36] [37] [38] [39] [40] [41] . Most recently, the association was confirmed in a Greek population of 146 sarcoidosis patients and 90 controls [42] . Sequencing of the coding and neighboring intronic regions of the BTNL2 gene in these individuals revealed the existence of 37 different variants, of which 12 were synonymous and 25 nonsynonymous substitutions. Thirteen of the 37 variants were predicted to affect gene function, including four yet unknown variants. In light of the small sample size in this study, it remains to be elucidated whether one or several of these variants confer additional independent genetic effects.
Annexin 11 is a protein involved in the regulation of apoptosis [43] and might influence the stability of sarcoid granulomas. Based on a genome-wide association study, variants in the ANXA11 gene which codes for Annexin 11 were found to be associated with sarcoidosis [44] and confirmed in independent populations of German, Czech, Portuguese and European and African American origin [37, [45] [46] [47] [48] . Evidence has recently been substantiated by a report on ANXA11 variants being associated in a Han Chinese population of 412 patients and 418 healthy controls [49 & ]. In a tagging-SNP approach, Feng et al. investigated 29 highfrequency SNPs (MAF > 0.2) in the ANXA11 gene region and found significant differences in the allele frequency for three variants. Consecutive multi-SNP modeling showed that the nonsynonymous SNP rs1049550 (R230C) completely explains this association, whereas rs2789679 and rs2819941 did not represent independent signals in this population.
In a sarcoidosis admixture linkage scan, nine regions were suggested to be linked to either West African or European ancestry [50] . Most recently, a refined analysis of those regions by Levin et al. showed the most significant sarcoidosis admixture linkage to a non-HLA loci on chromosome 17p13.1--13.3 could be explained by one SNP, rs6502976, that accounted for the majority of the admixture linkage signal in the region [51 & ]. SNP rs6502976 is located in intron 5 of the XAF1 gene region and is suggested to influence transcriptional expression of XAF1, which is a negative regulator of XIAP. The XIAP/XAF1 pathway is known to be involved in apoptotic mechanisms. For sarcoidosis, differential expression patterns of XAF1 and XIAP in granulomas suggest that this pathway may play a role in granuloma maintenance [51 & ]. Because of its novelty, this genetic finding now awaits replication in independent study populations and further functional exploration.
Most thoroughly investigated in candidate gene studies on sarcoidosis, the tumor necrosis factor (TNF) gene encodes a well known proinflammatory cytokine that acts on macrophage activation, promotion of cellular migration toward the site of inflammation and leukocyte adhesion (reviewed in [52] ). Further, TNF is targeted in sarcoidosis therapy by TNF-antibodies, such as infliximab or adalimumab. Summarizing 12 sarcoidosis case-control studies, a very recent meta-analysis including 3218 participants highlighted the TNF-308G/A variant being associated with sarcoidosis in populations of Asian and Caucasian ethnicity, and within patients with Löfgren syndrome [53] , with the A allele conferring increased risk. Regarding the clinically important subphenotype of cardiac sarcoidosis, a very recent publication in a Greek population of 173 patients reported the A allele being significantly associated [54] . This is in line with a long-standing finding in Japanese sarcoidosis patients [55] . The same polymorphism was reported to correlate with the response to TNF-inhibitor treatment [56 && ]. Wijnen et al. followed 111 patients receiving TNF-inhibitor treatment for at least 1 year. They found that for patients with the GG-genotype, the probability of improving compared with remaining stable or deteriorating was three times higher (risk ratio ¼ 3.09) than in carriers of the A allele. In case of a successful replication, we expect that this finding will be of high importance in clinical management.
Granuloma formation in sarcoidosis might be influenced by a number of additional risk variants, e.g., in the IL23R and NOTCH4 gene regions or in genes encoding Toll-like receptors. As these findings had been reported and reviewed previously [6] , they will not be discussed in detail here.
CONCLUSION
Granuloma formation in sarcoidosis is a complex phenomenon that is most likely influenced by genetic sarcoidosis risk factors in several aspects. As illustrated by this review, antigen presentation (HLA-DRB1), immune cell activation (BTNL2, TNF, IL23R) and regulation of apoptosis (ANXA11, XAF1) might be key players. As demonstrated for HLA class II associations, further investigation of subclassifications of disease phenotypes may provide deeper insights into genetically determined mechanisms that steer the disease pathophysiology down a certain pathway -including the interaction of multiple genes in a pathway -hopefully leading to more targeted and effective disease therapies. Although studies of multiple ethnic groups increase the complexity of sarcoidosis genetics, they at the same time can help us to better understand the underlying genetic heterogeneity of certain disease phenotypes. The challenge that lies ahead is teasing apart the genetic heterogeneities that exist across ethnic groups to make a more complete picture of the genetic landscape of this disease and to understand its role in disease pathogenesis. This knowledge can be applied in the upcoming era of precision medicine in which a patient's genotype will be an important determinant of his or her treatment strategies.
